Fennec Pharmaceuticals received FDA approval for Pedmark, a drug addressing cisplatin-induced ototoxicity in pediatric patients. The National Comprehensive Cancer Network (NCCN) and the European ...
Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.
Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 ...
Fennec's drug, Pedmark, has FDA approval for cisplatin-triggered ototoxicity in pediatric patients. Its market position is strengthened by notable endorsements and potential European Commission ...
Fennec Pharmaceuticals (NASDAQ:FENC) reported second quarter 2025 earnings on August 14, 2025, GAAP net product sales of $9.7 million, up 33% year over year compared to the same period last year and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results